GSEP
HAE icon

Golden State Equity Partners’s Haemonetics HAE Stock Holding History

Golden State Equity Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$750K Hold
11,863
– – 0.38% 76
2021
Q4 		$629K Buy
11,863
+637
+6% +$38.8K 0.32% 79
2021
Q3 		$792K Hold
11,226
– – 0.32% 74
2021
Q2 		$748K Buy
+11,226
New +$794K 0.29% 89

Other funds holding HAE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
LCOV
London Company of Virginia Richmond, Virginia $17.5B AUM 29.92% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return

Golden State Equity Partners's HAE Position: Q1 2022 in Review

Golden State Equity Partners held its Haemonetics (HAE) position steady in Q1 2022 at 11,863 shares worth $750K. The position accounts for 0.38% of the portfolio, ranked #76.

Golden State Equity Partners first reported a position in HAE in Q2 2021 and has held it in 4 quarters since. The position peaked at $792K in Q3 2021. 242 funds tracked by Wall St. Rank hold HAE as of Q1 2022.

  • Golden State Equity Partners held 11,863 shares of Haemonetics worth $750K as of Q1 2022.
  • Golden State Equity Partners left its Haemonetics share count unchanged in Q1 2022.
  • Haemonetics made up 0.38% of Golden State Equity Partners's portfolio in Q1 2022, its #76 holding.
  • Golden State Equity Partners first reported a position in Haemonetics in Q2 2021 and has held it in 4 quarters since.
  • Golden State Equity Partners's Haemonetics position peaked at $792K in Q3 2021.
  • 242 funds tracked by Wall St. Rank held Haemonetics as of Q1 2022.

Based on Golden State Equity Partners's 13F filing for Q1 2022, filed 16 May 2022.